drugset / Trial / NCT00128492

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)

NCT00128492

Phase 3 Completed 274 enrolled Gilead Sciences
Non-randomizedOpen-labelTreatment

Summary

The purpose of this study was to evaluate the safety and efficacy of multiple courses of AZLI in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).

Timeline

Start
2005-08
Primary completion
2008-11
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Aztreonam Small molecule 75 mg Inhaled

Indications